A repression of gene activity in the brain appears to be an early event affecting people with Alzheimer's disease, researchers funded by NIH have found.

A single dose of an experimental gene therapy boosted production of a missing blood-clotting factor in people with hemophilia, a new study shows.

Results from studies presented March 6 at the Conference on Retroviruses & Opportunistic Infections in Seattle demonstrated the importance of identifying & treating HIV-infected infants within the first year of life to prevent harm to the immune system & to enable normal neurological development.

A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease (NOMID).

With the launch of a new clinical trial supported by NIH, researchers are working to determine whether treating children diagnosed with the most severe form of fatty liver disease with a drug called cysteamine will help improve the liver.

Mutations in a gene called XRCC2 cause increased breast cancer risk, according to a study in the American Journal of Human Genetics.

Acorda Therapeutics' Ron Cohen presented testimony on the importance of federal policies to support the biotechnology industry at a House Committee on Science, Space and Technology, Subcommittee on Technology and Innovation hearing on March 27, a summary of his testimony is presented here

The House and Senate passed H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. It is now headed to the White House for President Obama’s signature.

In 2010, the Therapeutic Discovery Project (TDP) awarded $1 billion in tax credits to about 2,923 small biotechnology companies across the country to accelerate discovery of promising, cutting-edge cures to treat devastating diseases like cancer, heart disease, diabetes, and Alzheimer’s.

National Ag Day is a day to recognize and celebrate the abundance provided by agriculture. And today’s modern agriculture practices are more beneficial than ever before for the environment, the economy, food security and consumers.

The Biotechnology IndustryOrganization (BIO) is grateful for the opportunityto respond to theIndian Guidelines on Similar Biologics:Regulatory Requirements for Marketing Authorization, hereafterreferred to as"Guidelines".

About BIO andthe Biotechnology Industry

The 14th Annual BIO CEO & Investor Conference was held on February 13-14 in New York City at the Waldorf=Astoria

Panelists at the CEO & Investor Conference discuss the state-of-play on valuation for emerging biotech companies

State governments in 2011 continued to see regional economic growth in the life sciences industry and in 2012 will increasingly focus attention on technology transfer and venture funding as mechanisms to increase private sector innovation related activities within their jurisdictions. Realizing that entrepreneurship is a key ingredient in economic development, states and localities are undertaking the support of programs that assist high technology businesses, and that capitalize on state regional presence of universities and federal laboratories.

The 2011 Biotechnology Institute International BioGENEius Challenge winner will present at the White House Science Fair taking place this week in our nation’s capitol.

This document is a primer on industrial biotechnology.

President Obama has said, “the Administration will develop a National Bioeconomy Blueprint detailing steps to harness biological research innovations to address national challenges in health, food, energy, and the environment.”


February3, 2012


L. Daniel Mullaney

Assistant U.S. TradeRepresentative for Europeand the MiddleEast

Officeof theU.S. TradeRepresentative

600 17th Street NW Washington, DC 20508

Re: U.S.-EU HighLevel Working GrouponJobs andGrowth

Industrial biotechnology covers the application of biotechnology-based tools to traditional industrial processes (“bioprocessing”) and the manufacturing of bio-based products (such as fuels, chemicals and plastics) from renewable feedstocks.

BIO CEO & Investor Conference will be held February 13-14 in New York City.

Check out all of the everyday products you use that are now made from industrial biotechnology processes, which benefit you and reduce impact on the environment.

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Drugs approved with companion diagnostic tests represent the next wave of personalized medicine and have the potential to significantly improve patient outcomes.

Industrial & Environmental — Develops biotechnology industry policy on environmental and industrial biotechnology issues, promotes the use of industrial enzymes, conversion of biomass to energy and chemicals, and innovative clean up technologies.